Regulatory 2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study PDF Presentation Webcast Excel
2022-08-11 | Ascelia Pharma to present Orviglance Food Effect Study at 2022 RSNA Annual Meeting PDF Presentation Webcast Excel
2022-06-20 | Ascelia Pharma appoints Déspina Georgiadou Hedin as new CFO PDF Presentation Webcast Excel
2022-06-01 | Results from Orviglance comparison study to gadolinium presented at ESGAR 2022 conference PDF PDF Presentation Webcast Excel
2022-05-31 | Ascelia Pharma second US patent for Oncoral (oral irinotecan) strengthens coverage PDF Presentation Webcast Excel
Regulatory 2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals PDF Presentation Webcast Excel
2022-05-10 | Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal PDF Presentation Webcast Excel
Regulatory 2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022 PDF Presentation Webcast Excel
Regulatory 2022-04-11 | Ascelia Pharma publishes Annual Report for 2021 PDF Presentation Webcast Excel
Regulatory 2022-04-05 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Presentation Webcast Excel
Regulatory 2022-03-31 | Number of shares and votes in Ascelia Pharma AB PDF Presentation Webcast Excel
2022-03-22 | New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population PDF PDF Presentation Webcast Excel
2022-03-11 | Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study PDF Presentation Webcast Excel
Regulatory 2022-03-07 | Ascelia Pharma suspends clinical activities in Russia PDF Presentation Webcast Excel
2022-03-02 | Issue and repurchase of series C shares for share saving program PDF Presentation Webcast Excel
2022-02-15 | Results from Orviglance comparison study to gadolinium accepted for oral presentation at the ESGAR conference PDF Presentation Webcast Excel
Regulatory 2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent PDF Presentation Webcast Excel
